Tyrosine kinase inhibitors (TKIs) play an important role in cancer pharmacotherapy, yet there is limited data on their use during pregnancy. We studied placental disposition and placental toxicity of crizotinib, a TKI used to treat nonsmall cell lung cancer. Term placentas were perfused for 3 h with crizotinib (1 mM) using the ex vivo dual-side cotyledon perfusion technique. Interference of TKIs with trophoblast viability was studied using BeWo cells. Expression of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) in placental tissue was assessed by immunohistochemistry and inhibition of these transporters was determined in vitro by transport studies with membrane vesicles overexpressing human P-gp or BCRP. We found that crizotinib rapidly and strongly accumulates in cotyledon perfusion experiments, reaching a concentration of 3.1 6 0.4 mM in placental tissue. Final drug concentrations in the maternal and foetal reservoirs were 0.2 6 0.05 and 0.08 6 0.01 mM, respectively. Furthermore, crizotinib inhibited BeWo cell viability (IC50: 234 nM, 95% CI: 167-328 nM) 10 times more potently than other TKIs tested. In vitro transport studies revealed that crizotinib is a potent inhibitor of the transport activities of BCRP (IC50: 5.7 mM, 95% CI: 2.7-11.8 mM) and P-gp (IC50: 7.8 mM, 95% CI: 3.4-18.0 mM). In conclusion, crizotinib strongly accumulated in placental tissue at clinically relevant concentrations. IC50 values for transporter inhibition and trophoblast cell viability were similar to the tissue concentrations reached, suggesting that crizotinib can inhibit placental BCRP and P-gp function and possibly affect trophoblast viability.
Understanding the risks of the use of anticancer drugs during pregnancy has become important in the last decade. Since women become pregnant at a later age, the incidence of cancer during pregnancy has also increased (Peccatori et al., 2013) . Tyrosine kinase inhibitors (TKIs) play an increasingly important role in patient survival, yet there is limited data on the use of these drugs during pregnancy. Given the targeted mode of action of TKIs to inhibit proliferation of malignant cells, application of TKIs in pregnancy may be a safe therapeutic alternative compared with classical chemotherapy regimens, in terms of pregnancy outcome. Data on pregnancy outcome after TKI treatment are most extensively available for imatinib. For example, imatinib exposure in the first trimester is associated with the apparent occurrence of foetal malformations in 9.6% of 125 reported cases with known outcome (Pye et al., 2008) . This is lower than reported in pregnancies that were exposed to classical chemotherapeutic agents like cyclophosphamide (26.7%) and methotrexate (10.5%) (Gotestam Skorpen et al., 2016 ), yet still higher compared with the prevalence of malformations in the general population (2%) (EUROCAT, 2015) . At the same time, case studies describing outcome of pregnancy after imatinib exposure in the second or third trimester did not report foetal malformations (Pye et al., 2008) . Clearly TKIs comprise a very heterogeneous group of drugs that target many different tyrosine kinase pathways. To date, safety data on the use of most TKI class drugs is very limited, if any data are available at all (Lambertini et al., 2015) .
Here, we studied crizotinib, a TKI that is registered for the treatment of nonsmall cell lung carcinoma (NSCLC) in which tumors harbor anaplastic lymphoma kinase (ALK)-activating mutations. In cases in which pregnant women with NSCLC were eligible for crizotinib treatment, the baby was delivered preterm or treatment with crizotinib was postponed until after delivery (Neves et al., 2014; Sariman et al., 2013) . However, it is not known whether the risks of controlled preterm delivery outweigh the risks of treatment during pregnancy.
Although obvious teratogenicity by crizotinib was not reported in rodent reproductive studies, an increased post implantation loss was observed in rats at a dose equivalent to human exposure (50 mg/kg), indicating a possible effect on early foetal and/or placental development (EMA, 2012) . In addition, foetal weight loss was observed in both rats and rabbits at higher doses (200 mg/kg). Foetal exposure to crizotinib could lead to interference with ALK signaling, which might be harmful since this pathway is thought to play a role in the development of the nervous system (Iwahara et al., 1997; Vernersson et al., 2006) . Interestingly, ALK is also expressed in placental villous and extravillous trophoblasts (Ball et al., 2009) . Exposure to crizotinib and subsequent interference with ALK signaling could thus have consequences for placental function and indirectly affect foetal development. In addition, crizotinib might interfere with placental barrier function through inhibition of ATP-binding Cassette transporters (ABC transporters). Placental efflux transporters, in particular P-glycoprotein (P-gp, ABCB1) and Breast cancer resistance protein (BCRP, ABCG2), play an important role by actively transporting xenobiotics back into the maternal blood (Iqbal et al., 2012) .
In this study, we aimed to assess the placental transfer and interference with placental function of crizotinib. Using an ex vivo dual-side perfused human cotyledon model, placental transfer and tissue accumulation of crizotinib was determined. Furthermore, we conducted in vitro studies with a choriocarcinoma derived cell line (BeWo cells) to assess the potential of crizotinib and other TKIs to interfere with trophoblast cell viability. Last, inhibition of P-gp and BCRP was determined by means of in vitro transport studies with membrane vesicles derived from HEK 293 cells overexpressing these efflux transporters.
MATERIALS AND METHODS
TKIs and other chemicals. Crizotinib was purchased from Sigma (St Louis, Missouri, USA) and Sequoia Research (Pangbourne, United Kingdom). Sunitinib and sorafenib were purchased from Sequioa Research. Imatinib mesylate, erlotinib, gefitinib, dasatinib and tofacitinib citrate were purchased from Sanbio (Uden, The Netherlands). All substances had a purity of >97% and stock solutions were prepared in DMSO. Cisplatin (Cat No. P4394, Sigma), Elacridar (Cat No. SML0489, Sigma), and Ko143 (Cat No, K2144, Sigma) were purchased from Sigma and tritium labeled estrone sulfate was purchased from Perkin-Elmer (Waltham, Massachusetts, USA). Other chemicals were purchased from local suppliers with the highest purity possible.
Ex vivo dual-side cotyledon perfusion. Placentas from uncomplicated pregnancies were obtained from consenting women who underwent elective caesarean sections or vaginal delivery. For this study, approval of our institutional medical ethical committee was obtained (CMO Arnhem/Nijmegen File 2014 -1397 . Clinical details from the women whose placenta was used for perfusion experiments can be found in Table 1 .
Ex vivo dual-side cotyledon perfusions were performed as reported previously by Schalkwijk et al. (2016) . Briefly, maternal and foetal perfusion solutions consisted of Krebs-Henseleit buffer enriched with 10.1 mM glucose, 0.5 ml/l heparin 5000 IU and 30 g/l human albumin (Albuman). Solutions were oxygenated with 95% O2/5% CO 2 and kept at 37 C during the whole experiment. Upon arrival of the placenta, a foetal artery and associated vein were cannulated from a single intact cotyledon establishing a foetal circulation of 6 ml/min. A maternal circulation of 12 ml/min was established by inserting 4 cannulas in the intervillous space at the maternal site of the cotyledon and by recirculating the perfusion solution that leaked from the intervillous space. The cotyledon was perfused for 180 min in which 13 samples were taken from both the foetal and maternal circulation. Samples were centrifuged for 3 min at 9000 rcf and supernatant was stored at À20 C.
Crizotinib was added to the maternal circulation at a concentration of 1 mM to mimic the in vivo peak plasma concentration at steady state of approximately 900 nM (Hamilton et al., 2015) . Antipyrine (100 mg/l), a freely diffusing marker molecule, was also added to the maternal circulation. To test the integrity of the capillary bed of the cotyledon, FITC-labeled dextran (40 kDa, 36 mg/l) was added to the foetal circulation. Perfusions in absence of a placental cotyledon were performed to exclude that drug disappearance from the perfusion medium was due to adherence to perfusion system components.
Determination of FITC-dextran and antipyrine in the perfusion medium. The amount of FITC-dextran was determined by measuring its fluorescence with a Multiwell Plate Reader (Perkin-Elmer, excitation/emission: 485/530 nm). For antipyrine measurements, perfusion samples were deproteinized with 6% perchloric acid. Subsequently, a reaction mix consisting of 0.2 mg/ml NaNO 2 and 0.6% concentrated H 2 SO 4 , was added to the perfusion samples (1:1). Formed nitroantipyrine was determined via absorbance measurements at 350 nm, using a Biorad Multiwell Plate reader.
LC-MS/MS analyses of crizotinib. Placental tissue samples were prepared by making a 20% homogenate in water using a T 10 respectively. Argon was used as collision gas at a pressure of 1.5 mTorr. Detection of crizotinib was based on isolation of the protonated molecular ion, Cell viability assay. BeWo cells were exposed to crizotinib and other TKIs in a concentration range of 100 nM to 100 lM for 48 h at 37 C. TKIs were all dissolved in DMSO resulting in a final solvent concentration of 1% in all wells. A 1% DMSO control was set at 100% cell viability and effects of TKIs were compared relative to this condition. The medium was removed and cells were incubated with approximately 1 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-ditetrazolium bromide (MTT). MTT is reduced to formazan in mitochondria, which can only occur in viable cells. After 4 h at 37 C, the medium was removed and 50 ll DMSO was added to each well to dissolve the formazan which absorbance was measured at 540 nm using a Biorad Multiwell Plate reader. Cisplatin (100 lM) was used as a positive cytotoxic control.
Transport studies with membrane vesicles. Membrane vesicles derived from HEK293 cells overexpressing BCRP, P-gp or enhanced yellow fluorescent protein (EYFP) were obtained from PharmTox Services (Nijmegen, The Netherlands, www.pharm tox.nl; last accessed September, 2016). A rapid filtration technique was applied to measure transporter-specific substrate uptake into the vesicles as performed by Gozalpour et al. (2014) . The potency of crizotinib to inhibit transport of prototypical substrates of these transporters into the membrane vesicles was assessed for a concentration range of 100 nM to 100 lM. A reaction mix was prepared containing Tris-sucrose buffer (TS buffer, pH 7.4) supplemented with MgCl 2 (10 mM), either adenosine triphosphate (ATP, 4 mM) or adenosine monophosphate (AMP, 4 mM), prototypical substrate (1 mM N-methyl-quinidine for P-gp and 0.1 mM 3 H-estrone-3-sulfate for BCRP) and different crizotinib concentrations. Crizotinib was diluted to the required end concentrations in reaction mix from 100-fold stock solutions prepared in DMSO. Hence DMSO concentrations in all incubate was 1%. A wells plate was filled with 5 ll of purified membrane vesicles overexpressing a single transporter (total amount of protein: 7.5 mg) and 25 ll reaction mix. The plate was mixed and incubated in a water bath at 37 C for 1 min.
Incubation was stopped on ice and 150 ll ice-cold TS buffer was added to each well. Samples were transferred to a prewashed glass fibre filter plate (Millipore, Darmstadt, Germany) and filtered using a MultiScreenHTS-vacuum manifold filtration device (Millipore). The filters were washed twice with TS buffer. For BCRP vesicles, filters were collected and 2 ml of Opti-fluor scintillation fluid (PerkinElmer) was added. Samples were left to homogenize for 1 h after which they were counted using a liquid scintillation counter. For P-gp vesicles, 50% methanol (MeOH) with 0.1% formic acid was added to the filters after which substrate concentrations were measured by LCMS-MS (see below). Control uptake was quantified by measuring substrate uptake into vesicles overexpressing EYFP. EYFP control uptake values were subtracted from uptake values in the presence of crizotinib. Functionality of the transporters was evaluated by assessing transport differences in the presence of AMP or ATP and by the addition of known inhibitors of BCRP (Ko143, 5 mM) and P-gp (Elacridar, 10 mM).
N-Methylquinidine LC-MS/MS analyses.
One microliter of the supernatant of the filters in MeOH was injected onto the LC-MS/ MS system that consisted of an Accela HPLC system (Thermo scientific) equipped with a C18 UPLC column (Acquity UPLC BEH C18, 1,7 mm, 2.1 Â 50 mm, Waters). Separation was performed at a flow rate of 350 ml/min with eluent A (0.1% formic acid in water) and eluent B (0.1% formic acid in acetonitrile) under the following gradient conditions: 0 min, 100% eluent A, 3 min, 70% eluent A, 3.1 min, 100% eluent A, 6 min, 100% eluent A. The eluate was directly passed into a TSQ Vantage tandem mass spectrometer (Thermo scientific) equipped with an electro-spray ionization source. Positive electrospray ionization was achieved using nitrogen as a sheath gas with ionization voltage at þ3.5kV. The capillary temperature and the vaporizer temperature were set at 207 C and 382 C respectively. Argon was used as collision gas at a pressure of 1.5 mTorr. Detection of NMQ was based on isolation of the protonated molecular ion, [M þ H]þ, and subsequent MS/MS fragmentations and selected reaction monitoring were performed. The following SRM transitions were used: m/z 339.1(parent ion) to m/z 58.0, 94.0, 117.0, and 160.0 (all product ions). During the LC-MS/MS analysis, a timesegment program was developed to switch the divert valve of the mobile phase to waste or detection mode to prevent ion suppression and contamination of the ion source.
Immunohistochemistry. Fresh placental tissue was fixed in 10% formalin in phosphate buffered saline (PBS). After dehydration, tissue samples were embedded in paraffin. Sections of 4 lm were cut, dried, deparaffinised and rehydrated in ethanol to PBS. Antigen retrieval was performed using sodium citrate buffer (pH6) at 98 C for 15 min. After cooling and washing with PBS containing 0.1% Tween20 (PBST), endogenous peroxidase was blocked by incubating the sections with 3% H 2 O 2 in PBST, for 30 min. Aspecific-binding epitopes were blocked with 1% BSA in PBST for 30 min at RT. Sections were stained via standard indirect immunohistochemical staining techniques. P-gp was detected using a rabbit antihuman P-gp polyclonal antibody (Cat. No. HPA002199, Sigma) at a dilution of 500Â, followed by incubation of secondary biotin-conjugated swine-antirabbit polyclonal (Cat. No. E0431, DAKO, Glostrup, Denmark) at a dilution of 1000Â. For BCRP, mouse anti human BCRP monoclonal antibody (Cat. No. MC-236, Kamiya Biomedical Company, Seattle, Washington, USA) was used at a dilution of 50Â, followed by incubation of secondary biotin-conjugated goat-antimouse polyclonal antibody (Cat. No. B7264, Sigma) at a dilution of 500Â. Primary antibodies were incubated over night at 4 C and the secondary antibody was applied for 30 min at RT. Signals were amplified using a standard avidin-biotin complex (Brunschwig Chemie, Amsterdam, The Netherlands) for 30 min at RT. Antibody localization was visualized with 3,3 0 -diamino benzidine and nuclear counterstaining was performed using hematoxylin. Sections were evaluated using a VisionTek live digital microscope (Sakura, Alphen aan de Rijn, The Netherlands) and microphotographs were made using the accompanying software at an original magnification of 100Â.
Data and statistical analyses. Construction of graphs and data analyses was performed with GraphPad 5.03. A nonlinear curve fit was used for dose response curves (Y ¼ Bottom þ (TopBottom)/(1 þ 10 ((LogIC50-X)*HillSlope))) with the top of the curve constraint to 100% and the bottom to 0% for the MTT assays. For dasatinib, only the bottom was constraint to 0% and for erlotinib only the top was constraint to 100%, to minimize the effect of data points below 0% or above 100%, respectively. To assess the effect of the positive controls for the MTT assay and transport studies, a 2-sided independent Student's t test was conducted when 2 conditions were compared. When more than 2 conditions were compared, an ANOVA with Bonferroni post hoc correction for repeated measures was used. Mean differences were considered significant if P < .05. Crizotinib recovery calculations were based on an estimated average cotyledon weight of 42 g (Barker et al., 2013) and estimated added concentration of 1 mM.
RESULTS

Placental Transfer and Tissue Accumulation of Crizotinib
Only placenta perfusions that were conducted successfully, ie, with minimal leakage of fluid and minimal transfer of FITC-dextran were included (n ¼ 3, Figure 1 ). The placental transfer of the passive diffusion marker antipyrine is displayed in Figure 2A and reached equal concentrations in maternal and foetal circulations in all experiments. This confirmed good overlap between maternal and foetal circulations in the ex vivo cotyledon perfusion preparations. Figure 2B shows the placental transfer of crizotinib. Concentrations in the maternal reservoir rapidly decreased during the first hour of the perfusion, while only a small fraction could be retrieved from the foetal circulation. The transfer pattern is thus clearly different from that of antipyrine, the passive diffusion marker. Crizotinib concentrations in the maternal and foetal compartments at the end of the experiment were 0.2 6 0.05 and 0.08 6 0.01 mM, respectively. Crizotinib disappeared rapidly from the maternal perfusate and only small amounts appeared in the foetal perfusate, which indicates rapid metabolic conversion or avid accumulation in placental tissue. Measured tissue concentrations in the perfused cotyledon (3.1 6 0.4 mM, Figure 3 ) were significantly higher than in the foetal and maternal reservoirs at the end of the perfusion experiments (P < .01). The total crizotinib recovery at the end of the experiment was estimated to be 83 6 11% of the nominal added dose of which 59 6 8% was retrieved from the perfused cotyledon, which excludes an important influence of biotransformation.
Interference With Viability of BeWo Cells
To assess the potential of crizotinib and other TKIs to interfere with trophoblast function, cell viability assays using BeWo cells were conducted. Cisplatin was used as a positive control and significantly reduced cell viability ( Figure 4A ). Crizotinib inhibited cell viability with an IC50 of 234 nM (95% CI: 167-328 nM) ( Figure  4B ). All other TKIs inhibited cell viability at IC50s between 3.1 and 13.5 mM (Figs. 4C-H) . Hence, crizotinib was 10 times more potent than other TKIs in reducing viability in this cell model.
Inhibition of Placental Drug Efflux Transporters by Crizotinib
P-gp and BCRP expression in placental syncytiotrophoblasts was confirmed by immunohistochemical staining of formalinfixed placental tissue sections (Figs. 5A and 6A). Transport studies were performed in membrane vesicles derived from HEK293 cells overexpressing either P-gp or BCRP. Both transport assays showed a significantly enhanced substrate transport in the presence of ATP compared with incubations in which ATP was replaced by AMP (P < .001, Figs. 5B and 6B). ATP-dependent transport in EYFP-expressing control vesicles was also significantly lower than in BCRP and P-gp expressing vesicles (Figs. 5B and 6B). The established inhibitors Ko143 and elacridar significantly reduced BCRP and P-gp transport, respectively (Figs. 5C and 6C). We then found that crizotinib potently inhibited substrate transport by BCRP ( Figure 5D ) and P-gp ( Figure 6D ) with IC50 values of 5.7 mM (95% CI: 2.7-11.8 mM) and 7.8 mM (95% CI: 3.4-18.0 mM), respectively. We investigated, but did not observe any inhibitory effect of crizotinib on multidrug resistanceassociated protein 1 and protein 3 (data not shown).
DISCUSSION
TKIs consist of a wide variety of drugs with distinct physiochemical properties. Given their targeted mode of action and the fact that these drugs are increasingly applied during pregnancy, it has become important to study the safe use of these drugs during gestation. In the present study, we focused on the ALK inhibitor crizotinib, of which safety data during pregnancy is lacking. Since foetal or placental exposure to crizotinib could harm the unborn child, the main goal of this study was to determine the placental disposition of crizotinib in the ex vivo cotyledon perfusion model. Crizotinib is rapidly taken up in the placental cotyledon after administration to the maternal perfusate and crosses the placental barrier only to a small extent. Although passage into the foetal circulation was found to be relatively low, the high placental tissue concentrations that are reached could impair trophoblast cell viability and placental barrier function. Clinical trials aimed at determining in vivo placental passage parameters of drugs during pregnancy cannot be performed for understandable ethical reasons, and as placentation in common laboratory animals is quite dissimilar from humans (Pentsuk and van der Laan, 2009) , it is also difficult to translate data on placental transfer from animal studies to the human situation. To date, the ex vivo cotyledon perfusion model is the gold standard in predicting placental transfer and results from such experiments resemble reported umbilical cord-to-maternal blood concentration ratios for various types of drugs in the clinic, for example antiretroviral agents (McCormack and Best, 2014) , TKIs (Jovelet et al., 2015) , or biologicals (Porter et al., 2016) .
We found that crizotinib is strongly retained in placental tissue. Based on the nominal added concentration of 1 mM and an average cotyledon weight of 42 g (Barker et al., 2013) , even >50% of the added crizotinib could be retrieved in the perfused cotyledon. This is much higher than for other TKIs. Recently, Jovelet et al. (2015) reported a placental uptake of only 3% or less for gefitinib, imatinib, and erlotinib. Indeed, crizotinib is a lipophilic compound exhibiting relatively low water solubility and hence a higher affinity for lipophilic structures and proteins within placental tissue can be expected. Interestingly, lipophilicity, as reflected by logP values (octanol:water partition coefficient), does not differ substantially between the TKIs studied in placenta perfusion experiments, as measured LogP values range from 2.5 for crizotinib to only 3 for imatinib. Hence, crizotinib is in fact the least lipophilic of the drugs investigated in placenta perfusion studies (Jovelet et al., 2015; O'Brien and Fallah Moghaddam, 2013) , which is in contrast with the fact that this drug exhibits the highest accumulation in placental tissue. Also binding to plasma proteins is not substantially different 
FIG. 3.
Final crizotinib concentrations in placental, foetal and maternal compartments at t ¼ 180 min. Crizotinib levels in placenta tissue were significantly higher than in foetal and maternal reservoirs (** P < .01). Bars represent mean crizotinib concentrations 6 SEM of 3 independent placenta perfusions. The final concentrations in the tissue, foetal and maternal compartments were 3.1 6 0.4, 0.08 6 0.01, 0.20 6 0.05 mM, respectively. between these TKIs (90% for gefitinib, 91% for crizotinib, 93% for imatinib, and 94% for erlotinib), and does not appear to explain the difference in placental disposition observed.
Alternatively, the ion-trapping hypothesis may play a role in the placental disposition of crizotinib. Since crizotinib is a basic compound, protonation of tertiary nitrogen atoms in acidic   FIG. 4 . Inhibition of cell viability in BeWo cells by TKIs after 48 h exposure. A, The cytotoxic drug cisplatin inhibited cell viability significantly (*** P < .001). B-H, Doseinhibition curves of the ALK inhibitor crizotinib (B), the EGFR inhibitors erlotinib (C) and gefitinib (D), the BCR-ABL1 inhibitors imatinib (E) and dasatinib (F) and the VEGFR inhibitors sorafenib (G) and sunitinib (H). Data points represent mean percentage of viable cells 6 SEM of 3-4 experiments, each performed in triplicate. IC50 values with their corresponding 95% CI are given within the graphs. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; BCR-ABL1, break cluster region-Abelson murine leukemia viral oncogene homolog 1 fusion protein; VEGFR, vascular endothelial growth factor receptor. subcellular compartments may lead to ionization and subsequent trapping of the charged molecules in, for example, lysosomes. In addition, positively charged crizotinib molecules may bind to negatively charged phosphate head groups of phospholipids present in cell membranes, which can further contribute to the observed tissue affinity. Of the TKIs studied in placenta perfusion studies, crizotinib indeed is the strongest base (O'Brien and Fallah Moghaddam, 2013) . Also the high volume of distribution of crizotinib observed in clinical pharmacokinetic studies (Hamilton et al., 2015) , is well in line with a high tissue affinity in general. Moreover, in animal experiments crizotinib consistently displayed a higher volume of distribution than imatinib, gefitinib, and erlotinib (O'Brien and Fallah Moghaddam, 2013) . Therefore, it appears that the placental accumulation of crizotinib may still be explained by its physicochemical properties. However, future studies should focus on the possible role of target-specific binding (eg, to ALK) and transporter-mediated processes in the placental accumulation of crizotinib.
Given the strong placental accumulation of crizotinib, we hypothesized that this could have implications for placental function.
To this end, we tested to what extent crizotinib affected trophoblast viability in an in vitro model using BeWo cells. Next to its high retention in placental tissue, crizotinib also inhibited cell viability 10 times more potently than the other TKIs tested. To our knowledge, gefitinib is the only TKI of which the effect on cell viability of trophoblasts was tested. Gefitinib (2-8 mM) significantly reduced cell viability in multiple cell models, which is in line with our findings (Nilsson et al., 2013) . Despite the fact that TKIs are drugs of the same class, they behave differently in this in vitro cell model with respect to effects on cell viability.
Receptor tyrosine kinases play an essential role in physiological cell proliferation and migration, but can also thrive malignant cell transformation. As the placenta is a highly proliferative organ, trophoblasts share numerous tyrosine kinase pathways with cancer cells. The TKIs tested in our in vitro model target a variety of receptor tyrosine kinases, among which are ALK, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor (VEGFR). ALK (Ball et al., 2009) , EGFR, and VEGFR are expressed in cytotrophoblastderived placental cells (Ferretti et al., 2007) 3H-estron-3-sulfate (3H-E1S) transport in EYFP control vesicles with ATP was significantly lower than transport in BCRP vesicles with ATP (*** P < .001). Also, transport was significantly enhanced in the presence of ATP compared with BCRP vesicles in the presence of AMP (***P < .001). C, Addition of Ko143 significantly reduced 3H-E1S transport (***P < .001) (results of a single representative experiment). D, A concentration-dependent 3H-E1S transport inhibition by crizotinib in BCRP vesicle transport assays. Data points represent the mean 3H-E1S transport (% of control) 6 SEM for 2-3 experiments. The corresponding IC50 values and 95% CIs are given in the graph. BCRP, breast cancer resistance protein; EYFP, enhanced yellow fluorescent protein; 3 H-E1S, 3 H-estrone-3-sulfate Interestingly, we could not confirm ALK expression in placental tissue or demonstrate it in BeWo cells by means of western blotting. Possibly, the potent inhibitory effect of crizotinib on BeWo cell viability might be resulting from an effect on other tyrosine kinases, since crizotinib is a multi-targeted TKI and was originally designed as a hepatocyte growth factor receptor inhibitor (Cui et al., 2011) . Furthermore, as BeWo cells are a choriocarcinoma-derived cell line, these findings should be interpreted with caution and need to be corroborated in primary isolated trophoblast cultures. Impairment of cell viability in vitro may be reflective of impaired placental development in patients, possibly increasing the risk for adverse pregnancy outcome (Higgins et al., 2015; Norwitz, 2006) . Therefore, based on our present data we encourage collection of placentas from women that were exposed to crizotinib as well as other TKIs on a case-by-case basis to further investigate such an effect. Throughout pregnancy, the placental efflux transporters P-gp and BCRP play an important role in protecting the foetus from xenobiotics (Iqbal et al., 2012) . P-gp and BCRP are the most studied transporters with respect to the human placenta. They are both expressed at the maternal-facing membrane in placental syncytiotrophoblasts and actively transport xenobiotics from the interior of the cells back into the maternal circulation. Crizotinib inhibited P-gp and BCRP transport activity with an IC50 of 5.7 and 7.6 mM, respectively. Crizotinib was found to be a P-gp and BCRP inhibitor in vitro, based mainly on indirect measurements (eg, in cell or animal studies in which P-gp-mediated multidrug resistance is reversed by crizotinib) (Orbach and Zineh, 2011; Zhou et al., 2012) . To our knowledge, we are the first to report full dose-inhibition curves of P-gp and BCRP activity directly, which allows us to establish inhibitory potencies and compare these with actual concentrations of crizotinib reached in the placenta. The IC50 values for transport inhibition are, like placental tissue concentrations, within the micromolar range, from which we can conclude that crizotinib can inhibit BCRP and P-gp in the placenta at clinically relevant concentrations. Crizotinib-mediated inhibition of these drug efflux transporters may consequently result in impaired placental barrier function and possible foetal and placental exposure to xenobiotics. It should be noted that the inhibitory effects we described were FIG. 6 . A, P-gp (brown) staining of placental tissue. ST, syncytiotrophoblast; CT, cytotrophoblast; FBV, foetal blood vessel; MBS, maternal blood space. Expression of Pgp appears to be mainly confined to syncytiotrophoblasts. B, AMP/ATP transport differences for EYFP and P-gp in a single representative experiment. NMQ transport in EYFP control vesicles with ATP was significantly lower than transport in P-gp vesicles with ATP (***P < .001). Also, transport was significantly enhanced in the presence of ATP compared with P-gp vesicles in the presence of AMP (***P < .001). C, Addition of elacridar significantly reduced NMQ (***P < .001) (results of a single representative experiment). D, A concentration-dependent NMQ transport inhibition by crizotinib in P-gp vesicle transport assays. Data points represent the mean NMQ transport (% of control) 6 SEM for 3 experiments. The corresponding IC50 values and 95% CIs are given in the graph. P-gp, P-glycoprotein; EYFP, enhanced yellow fluorescent protein; NMQ, N-methyl-quinidine. obtained using NMQ and E1S, as model substrates. Although these substrates are commonly used to monitor P-gp and BCRP function in general, it is possible that specific exogenous or endogenous substrates may bind to different binding pockets of these transporters and may therefore also be differentially affected by crizotinib. Further studies should reveal the actual mode of transporter inhibition by crizotinib.
Crizotinib is currently licensed for treatment of ALK-positive NSCLC but has been proposed advantageous for treatment of other types of cancer. For example, ALK-activating mutations also occur in anaplastic large cell lymphoma, neuroblastoma and Ewing sarcoma (Fleuren et al., 2013; Hallberg and Palmer, 2016) , which may result in a more frequent application of crizotinib in the future, thereby increasing the chance that this coincides with pregnancy.
In conclusion, we found that at clinically relevant concentrations, crizotinib accumulates in placental tissue, inhibits BCRP and P-gp and possibly affects trophoblast cell viability. In order to translate these findings into clinical practice, there is a need for clinical pharmacokinetic and pharmacodynamic studies to support the disposition and toxicity data as provided here. Should there in the future be cases in which women are exposed to crizotinib (or other TKIs) during pregnancy, it will be valuable to report these. This particularly includes collection of placental material, as this may be a tissue prone to crizotinib toxicity.
